

18 Aug 2024 | News

Quick Listen: Scrip's Five Must-Know Things

by Ian Haydock

In this week's podcast edition of Five Must-Know Things: Merck & Co. steps into CD19 bispecific space; gene therapy patients rise, but slowly; Madrigal's Rezdiffra plans; Korean biopharma financing recovering?; and approvals to watch out for in Q3.

Join us for an audio catch-up on the major events in the biopharma industry over the past business week, as reported by *Scrip's* global team, in this podcast version of Five Must-Know Things.

This episode covers insights for the business week ended 16 August 2024, including: [Merck & Co., Inc.](#) steps into CD19 bispecific space; gene therapy patients rise, but slowly; [Madrigal Pharmaceuticals, Inc.](#)'s Rezdiffra plans; Korean biopharma financing recovering?; and approvals to watch out for in Q3.

This and all our other podcasts are available on the *Citeline* channel on [Apple Podcasts](#), [Google Podcasts](#), [SoundCloud](#), [TuneIn](#) and [Spotify Podcasts](#), and via smart speakers if one of these platforms has been set up as your default podcast provider.

Stories mentioned in this episode:

(Also see "[Merck Steps Into CD19 Bispecific Antibody Ring With Curon Deal](#)" - Scrip, 9 Aug, 2024.)

(Also see "[Gene Therapy Patient Pipeline Builds, But Slowly, In Q2](#)" - Scrip, 14 Aug, 2024.)

(Also see "[Madrigal Likes Rezdiffra's Long-Term Positioning In NASH](#)" - Scrip, 9 Aug, 2024.)

(Also see "[Korean Biopharma Financings Remain In Doldrums But Recovery In Sight?](#)" - Scrip, 13 Aug, 2024.)

(Also see "[10 Approvals To Watch Out For In Q3](#)" - Scrip, 9 Aug, 2024.)

[Click here to explore this interactive content online](#) ✨